Brief: Rain Therapeutics Doses First Patient In Phase 2 Basket Trial Of Milademetan For MDM2-Amplified Advanced Solid Tumors
19/11/2021 13:09
Nov 19 (Reuters) - Rain Therapeutics Inc RAIN.O :
* RAIN THERAPEUTICS DOSES FIRST PATIENT IN PHASE 2 BASKET
TRIAL OF
MILADEMETAN FOR MDM2-AMPLIFIED ADVANCED SOLID TUMORS (MANTRA-2)
Source text for Eikon: ID:nGNXc0kdGB
Further company coverage: RAIN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rain Oncology
See all newsBrief: Rain Enhancement Technologies Holdco - May Offer Up To $25 Million In Securities From Time To Time - SEC Filing
Brief: Rain Enhancement Technologies Holdco Inc - Q1 And Q2 2025 Financial Statements Should Not Be Relied Upon Due To Accounting Error - SEC Filing
Brief: Rain Oncology Pursuant To Proposed Deal With Pathos AI
Brief: Rain Oncology To Be Acquired By Pathos AI For $1.16 In Cash Per Share Plus Contingent Value Rights
Brief: Rain Oncology Q3 Net Income USD -7.034 Million